Kestra Medical Technologies (NASDAQ:KMTS) Insider Brian Daniel Webster Sells 15,000 Shares

Kestra Medical Technologies, Ltd. (NASDAQ:KMTS) insider Brian Daniel Webster sold 15,000 shares of the firm’s stock in a transaction on Tuesday, February 17th. The stock was sold at an average price of $25.60, for a total transaction of $384,000.00. Following the completion of the sale, the insider owned 379,786 shares of the company’s stock, valued at $9,722,521.60. The trade was a 3.80% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this link.

Brian Daniel Webster also recently made the following trade(s):

• On Thursday, January 15th, Brian Daniel Webster sold 15,000 shares of Kestra Medical Technologies stock. The stock was sold at an average price of $22.80, for a total value of $342,000.00.
• On Monday, December 29th, Brian Daniel Webster sold 15,000 shares of Kestra Medical Technologies stock. The stock was sold at an average price of $26.59, for a total value of $398,850.00.

Kestra Medical Technologies Stock Up 2.1%

NASDAQ KMTS traded up $0.55 during trading hours on Friday, hitting $26.87. The company’s stock had a trading volume of 39,303 shares, compared to its average volume of 255,815. Kestra Medical Technologies, Ltd. has a 52 week low of $13.25 and a 52 week high of $30.00. The company has a current ratio of 5.47, a quick ratio of 5.47 and a debt-to-equity ratio of 0.26. The company’s 50-day simple moving average is $25.65 and its two-hundred day simple moving average is $23.61. The company has a market capitalization of $1.57 billion and a PE ratio of -8.48.

Institutional Investors Weigh In On Kestra Medical Technologies

A number of large investors have recently modified their holdings of KMTS. Price T Rowe Associates Inc. MD boosted its position in shares of Kestra Medical Technologies by 137.5% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 4,369,429 shares of the company’s stock valued at $115,878,000 after purchasing an additional 2,529,851 shares in the last quarter. Brown Advisory Inc. boosted its holdings in shares of Kestra Medical Technologies by 34.1% during the 4th quarter. Brown Advisory Inc. now owns 1,688,356 shares of the company’s stock valued at $44,775,000 after acquiring an additional 428,996 shares during the last quarter. Alliancebernstein L.P. grew its position in Kestra Medical Technologies by 13.7% in the 3rd quarter. Alliancebernstein L.P. now owns 1,491,970 shares of the company’s stock worth $35,449,000 after purchasing an additional 179,885 shares during the period. Eventide Asset Management LLC lifted its holdings in Kestra Medical Technologies by 5.4% in the fourth quarter. Eventide Asset Management LLC now owns 1,269,651 shares of the company’s stock valued at $33,671,000 after acquiring an additional 65,288 shares during the period. Finally, Franklin Resources Inc. boosted its holdings in shares of Kestra Medical Technologies by 180.8% in the fourth quarter. Franklin Resources Inc. now owns 951,008 shares of the company’s stock worth $25,221,000 after buying an additional 612,343 shares during the last quarter.

Analyst Ratings Changes

A number of equities research analysts have recently commented on the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Kestra Medical Technologies in a research note on Wednesday, December 24th. The Goldman Sachs Group set a $24.00 price objective on Kestra Medical Technologies in a report on Friday, January 16th. BTIG Research assumed coverage on shares of Kestra Medical Technologies in a report on Tuesday, November 18th. They issued a “buy” rating and a $32.00 price target on the stock. Piper Sandler increased their price target on shares of Kestra Medical Technologies from $27.00 to $30.00 and gave the stock an “overweight” rating in a report on Friday, December 12th. Finally, Stifel Nicolaus set a $30.00 price objective on Kestra Medical Technologies in a report on Friday, December 12th. Six analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $29.00.

About Kestra Medical Technologies

We are a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. We have developed and are commercializing our Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution. The cornerstone of our Cardiac Recovery System platform is the ASSURE WCD, a next generation wearable cardioverter defibrillator (“WCD”) used to protect patients at an elevated risk of sudden cardiac arrest (“SCA”), a major public health problem that accounts for approximately 50% of all cardiovascular deaths in the U.S.